With the evolution of nanomedicine, the past decades witnessed diversified nanomaterials as marvelous anti-tumor tools ushering in a new era of tumor diagnosis and treatment. Among them, two-dimensional layered nanomaterial as an emerging class of nanomaterials has one dimension less than 100 nm, showing a high specific area and the thinnest sheet-like structure (Liu S, Pan X, Liu H. Twodimensional nanomaterials for photothermal therapy. Angew Chem Int Ed 2020;59:5890-900). The discovery of graphene drove the exploration of various new two-dimensional layered nanomaterials for tumor diagnosis and treatment including graphene-based nanomaterials, black phosphorus (BP), transition metal dichalcogenides (TMDs), layered double hydroxides (LDHs), and bismuth oxyhalides (BiOX, X=F, Cl, Br, I) (Ma H, Xue MQ. Recent advances in the photothermal applications of two-dimensional nanomaterial: photothermal therapy and beyond. J Mater Chem 2021;9:17569). On the one hand, they exhibit strong near-infrared (NIR) absorption and the capacity of optimizing corresponding properties by adjusting the crystal structure. On the other hand, they own unique strengths such as fantastic physicochemical properties (graphene-based nanomaterials), high loading capacity (BP), distinct phase-dependent optical properties (TMDs), a specific chemical response to the tumor microenvironment (LDHs), and large X-ray attenuation coefficient (BiOX). Herein, we briefly introduce three typical two-dimensional layered nanomaterials, their prospects and future research priorities in tumor diagnosis and treatment are concluded.
随着纳米医学的发展,在过去的几十年里,各种各样的纳米材料作为神奇的抗肿瘤工具开创了肿瘤诊断和治疗的新时代。其中,二维层状纳米材料作为一类新兴的纳米材料,其一维小于100 nm,显示出高比面积和最薄的片状结构(Liu S,Pan X,Liu H.用于光热治疗的二维纳米材料。Angew Chem Int Ed 2020;59:5890-900)。石墨烯的发现推动了用于肿瘤诊断和治疗的各种新型二维层状纳米材料的探索,包括石墨烯基纳米材料、黑磷(BP)、过渡金属二硫属化合物(TMDs)、层状双氢氧化物(LDHs)和卤氧化铋(BiOX,X=F,Cl,Br,I)(马,薛MQ)。二维纳米材料光热应用的最新进展:光热疗法及其应用。《材料化学杂志》2021;9:17569)。一方面,它们表现出较强的近红外(NIR)吸收能力,并能够通过调节晶体结构来优化相应的性能。另一方面,它们具有独特的优势,如优异的物理化学性质(石墨烯基纳米材料)、高负载能力(BP)、独特的相依赖光学性质(TMDs)、对肿瘤微环境的特定化学反应(LDHs)和大的X射线衰减系数(BiOX)。在此,我们简要介绍了三种典型的二维层状纳米材料,总结了它们在肿瘤诊断和治疗中的前景和未来的研究重点。
{"title":"Two-dimensional layered nanomaterials for tumor diagnosis and treatment.","authors":"Chengyuan Hong, Zhusheng Liu, Tianxiang Chen, Aiguo Wu","doi":"10.1515/mr-2023-0006","DOIUrl":"10.1515/mr-2023-0006","url":null,"abstract":"<p><p>With the evolution of nanomedicine, the past decades witnessed diversified nanomaterials as marvelous anti-tumor tools ushering in a new era of tumor diagnosis and treatment. Among them, two-dimensional layered nanomaterial as an emerging class of nanomaterials has one dimension less than 100 nm, showing a high specific area and the thinnest sheet-like structure (Liu S, Pan X, Liu H. Twodimensional nanomaterials for photothermal therapy. Angew Chem Int Ed 2020;59:5890-900). The discovery of graphene drove the exploration of various new two-dimensional layered nanomaterials for tumor diagnosis and treatment including graphene-based nanomaterials, black phosphorus (BP), transition metal dichalcogenides (TMDs), layered double hydroxides (LDHs), and bismuth oxyhalides (BiOX, X=F, Cl, Br, I) (Ma H, Xue MQ. Recent advances in the photothermal applications of two-dimensional nanomaterial: photothermal therapy and beyond. J Mater Chem 2021;9:17569). On the one hand, they exhibit strong near-infrared (NIR) absorption and the capacity of optimizing corresponding properties by adjusting the crystal structure. On the other hand, they own unique strengths such as fantastic physicochemical properties (graphene-based nanomaterials), high loading capacity (BP), distinct phase-dependent optical properties (TMDs), a specific chemical response to the tumor microenvironment (LDHs), and large X-ray attenuation coefficient (BiOX). Herein, we briefly introduce three typical two-dimensional layered nanomaterials, their prospects and future research priorities in tumor diagnosis and treatment are concluded.</p>","PeriodicalId":74151,"journal":{"name":"Medical review (Berlin, Germany)","volume":"3 3","pages":"205-208"},"PeriodicalIF":0.0,"publicationDate":"2023-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/06/6a/mr-3-3-mr-2023-0006.PMC10542879.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41174269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-05-26eCollection Date: 2023-06-01DOI: 10.1515/mr-2023-0004
Ashish William, Molly Madan
The monkeypox virus, which causes the viral zoonotic disease, is known as the most significant orthopoxvirus infection following the elimination of smallpox. The monkeypox virus, which was previously exclusive to West and Central African nations and caused endemic diseases in monkeys and people, has recently been linked to human infections in non-endemic areas including the United States of America (USA) and more than 30 additional countries. Guidelines for the diagnosis and treatment of monkeypox have also recently been made available by the Ministry of Health and Family Welfare of India and the Indian Government. The monkeypox outbreak continues to be a worldwide health emergency, the highest degree of alert recognised by the World Health Organization. The Centers for Disease Control and Prevention (CDC) advises vaccination for those who have been exposed to the disease as well as those who may be at higher risk of contracting it, such as those who have been identified by public health officials as a contact of someone who has the disease.
{"title":"Monkeypox scenario in India: a review study.","authors":"Ashish William, Molly Madan","doi":"10.1515/mr-2023-0004","DOIUrl":"10.1515/mr-2023-0004","url":null,"abstract":"<p><p>The monkeypox virus, which causes the viral zoonotic disease, is known as the most significant orthopoxvirus infection following the elimination of smallpox. The monkeypox virus, which was previously exclusive to West and Central African nations and caused endemic diseases in monkeys and people, has recently been linked to human infections in non-endemic areas including the United States of America (USA) and more than 30 additional countries. Guidelines for the diagnosis and treatment of monkeypox have also recently been made available by the Ministry of Health and Family Welfare of India and the Indian Government. The monkeypox outbreak continues to be a worldwide health emergency, the highest degree of alert recognised by the World Health Organization. The Centers for Disease Control and Prevention (CDC) advises vaccination for those who have been exposed to the disease as well as those who may be at higher risk of contracting it, such as those who have been identified by public health officials as a contact of someone who has the disease.</p>","PeriodicalId":74151,"journal":{"name":"Medical review (Berlin, Germany)","volume":"3 3","pages":"270-276"},"PeriodicalIF":0.0,"publicationDate":"2023-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/82/9b/mr-3-3-mr-2023-0004.PMC10542878.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41143003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer nanomedicines require different, even opposite, properties to voyage the cascade drug delivery process involving a series of biological barriers. Currently-approved nanomedicines can only alleviate adverse effects but cannot improve patient survival because they fail to meet all the requirements. Therefore, nanocarriers with synchronized functions are highly requisite to capacitate efficient drug delivery and enhanced therapeutic efficacies. This perspective article summarizes recent advances in the two main strategies for nanomedicine design, the All-in-One approach (integration of all the functions in one system) and the One-for-All approach (one functional group with proper affinity enables all the functions), and presents our views on future nanomedicine development.
{"title":"\"One-for-All\" approach: a black technology for nanomedicine development?","authors":"Jiajia Xiang, Shiqun Shao, Zhuxian Zhou, Youqing Shen","doi":"10.1515/mr-2023-0003","DOIUrl":"10.1515/mr-2023-0003","url":null,"abstract":"<p><p>Cancer nanomedicines require different, even opposite, properties to voyage the cascade drug delivery process involving a series of biological barriers. Currently-approved nanomedicines can only alleviate adverse effects but cannot improve patient survival because they fail to meet all the requirements. Therefore, nanocarriers with synchronized functions are highly requisite to capacitate efficient drug delivery and enhanced therapeutic efficacies. This perspective article summarizes recent advances in the two main strategies for nanomedicine design, the All-in-One approach (integration of all the functions in one system) and the One-for-All approach (one functional group with proper affinity enables all the functions), and presents our views on future nanomedicine development.</p>","PeriodicalId":74151,"journal":{"name":"Medical review (Berlin, Germany)","volume":"3 2","pages":"184-187"},"PeriodicalIF":0.0,"publicationDate":"2023-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a3/6e/mr-3-2-mr-2023-0003.PMC10471114.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10311379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-04-18eCollection Date: 2023-04-01DOI: 10.1515/mr-2023-0002
He Ding, Yuxin Zhang, Yu Mao, Yan Li, Yan Shen, Jingyi Sheng, Ning Gu
Macrophage polarization is an essential process involved in immune regulation. In response to different microenvironmental stimulation, macrophages polarize into cells with different phenotypes and functions, most typically M1 (pro-inflammatory) and M2 (anti-inflammatory) macrophages. Iron-based nanoparticles have been widely explored and reported to regulate macrophage polarization for various biomedical applications. However, the influence factors and modulation mechanisms behind are complicated and not clear. In this review, we systemically summarized different iron-based nanoparticles that regulate macrophage polarization and function and discussed the influence factors and mechanisms underlying the modulation process. This review aims to deepen the understanding of the modulation of macrophage polarization by iron-based nanoparticles and expects to provide evidence and guidance for subsequent design and application of iron-based nanoparticles with specific macrophage modulation functions.
{"title":"Modulation of macrophage polarization by iron-based nanoparticles.","authors":"He Ding, Yuxin Zhang, Yu Mao, Yan Li, Yan Shen, Jingyi Sheng, Ning Gu","doi":"10.1515/mr-2023-0002","DOIUrl":"10.1515/mr-2023-0002","url":null,"abstract":"<p><p>Macrophage polarization is an essential process involved in immune regulation. In response to different microenvironmental stimulation, macrophages polarize into cells with different phenotypes and functions, most typically M1 (pro-inflammatory) and M2 (anti-inflammatory) macrophages. Iron-based nanoparticles have been widely explored and reported to regulate macrophage polarization for various biomedical applications. However, the influence factors and modulation mechanisms behind are complicated and not clear. In this review, we systemically summarized different iron-based nanoparticles that regulate macrophage polarization and function and discussed the influence factors and mechanisms underlying the modulation process. This review aims to deepen the understanding of the modulation of macrophage polarization by iron-based nanoparticles and expects to provide evidence and guidance for subsequent design and application of iron-based nanoparticles with specific macrophage modulation functions.</p>","PeriodicalId":74151,"journal":{"name":"Medical review (Berlin, Germany)","volume":"3 2","pages":"105-122"},"PeriodicalIF":0.0,"publicationDate":"2023-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/6c/d2/mr-3-2-mr-2023-0002.PMC10471121.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10311382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-04-17eCollection Date: 2023-04-01DOI: 10.1515/mr-2023-0005
Yingying Yu, Liangzhu Feng, Zhuang Liu
Cancer immunotherapy comprising of immune checkpoint blockade (ICB) therapy, immune cell therapies, cancer vaccines and many others represents a profound arsenal in the fight against different types of cancers. However, their overall clinical objective response rates, particularly against most solid tumors, are still not sufficient owing to a variety of reasons including the heterogenous expression of tumor antigens, limited tumor infiltration of effector immune cells, acquired tumor immunosuppression and some other factors. In recent years, various nanomedicine strategies have been proposed to assist cancer immunotherapy via distinct mechanisms, presenting new promises in many published studies. This perspective will thus provide a brief overview regarding the development of nanomedicine platforms for improving cancer immunotherapy.
{"title":"Nanomedicine sheds new light on cancer immunotherapy.","authors":"Yingying Yu, Liangzhu Feng, Zhuang Liu","doi":"10.1515/mr-2023-0005","DOIUrl":"10.1515/mr-2023-0005","url":null,"abstract":"<p><p>Cancer immunotherapy comprising of immune checkpoint blockade (ICB) therapy, immune cell therapies, cancer vaccines and many others represents a profound arsenal in the fight against different types of cancers. However, their overall clinical objective response rates, particularly against most solid tumors, are still not sufficient owing to a variety of reasons including the heterogenous expression of tumor antigens, limited tumor infiltration of effector immune cells, acquired tumor immunosuppression and some other factors. In recent years, various nanomedicine strategies have been proposed to assist cancer immunotherapy via distinct mechanisms, presenting new promises in many published studies. This perspective will thus provide a brief overview regarding the development of nanomedicine platforms for improving cancer immunotherapy.</p>","PeriodicalId":74151,"journal":{"name":"Medical review (Berlin, Germany)","volume":"3 2","pages":"188-192"},"PeriodicalIF":0.0,"publicationDate":"2023-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/78/44/mr-3-2-mr-2023-0005.PMC10471084.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10674620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-04-14eCollection Date: 2023-04-01DOI: 10.1515/mr-2023-0008
Wei Cao, Tian Xia
Rapid developments in the coronavirus disease 2019 (COVID-19) mRNA vaccine showcased the power of lipid nanoparticle (LNP) delivery systems in fighting infectious diseases. In addition, mRNA therapeutics are also in development for cancer immunotherapy. Recently, mRNA therapy has been expanded to induce immune tolerance, the opposite of immune-boosting effects, to treat diseases involving enhanced immune responses including allergies and autoimmune diseases. mRNA LNPs have been used to treat peanut allergy by us and autoimmune experimental autoimmune encephalomyelitis by Ugur Sahin. It is expected that more and more research is going to delve into the immune tolerance field for allergies and autoimmune diseases, where effective therapies are in short supply.
{"title":"mRNA lipid nanoparticles induce immune tolerance to treat human diseases.","authors":"Wei Cao, Tian Xia","doi":"10.1515/mr-2023-0008","DOIUrl":"10.1515/mr-2023-0008","url":null,"abstract":"<p><p>Rapid developments in the coronavirus disease 2019 (COVID-19) mRNA vaccine showcased the power of lipid nanoparticle (LNP) delivery systems in fighting infectious diseases. In addition, mRNA therapeutics are also in development for cancer immunotherapy. Recently, mRNA therapy has been expanded to induce immune tolerance, the opposite of immune-boosting effects, to treat diseases involving enhanced immune responses including allergies and autoimmune diseases. mRNA LNPs have been used to treat peanut allergy by us and autoimmune experimental autoimmune encephalomyelitis by Ugur Sahin. It is expected that more and more research is going to delve into the immune tolerance field for allergies and autoimmune diseases, where effective therapies are in short supply.</p>","PeriodicalId":74151,"journal":{"name":"Medical review (Berlin, Germany)","volume":"3 2","pages":"180-183"},"PeriodicalIF":0.0,"publicationDate":"2023-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8f/e9/mr-3-2-mr-2023-0008.PMC10471105.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10311384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-04-12eCollection Date: 2023-04-01DOI: 10.1515/mr-2022-0047
Ya-Nan Fan, Gui Zhao, Yue Zhang, Qian-Ni Ye, Yi-Qun Sun, Song Shen, Yang Liu, Cong-Fei Xu, Jun Wang
Immune cells are indispensable defenders of the human body, clearing exogenous pathogens and toxicities or endogenous malignant and aging cells. Immune cell dysfunction can cause an inability to recognize, react, and remove these hazards, resulting in cancers, inflammatory diseases, autoimmune diseases, and infections. Immune cells regulation has shown great promise in treating disease, and immune agonists are usually used to treat cancers and infections caused by immune suppression. In contrast, immunosuppressants are used to treat inflammatory and autoimmune diseases. However, the key to maintaining health is to restore balance to the immune system, as excessive activation or inhibition of immune cells is a common complication of immunotherapy. Nanoparticles are efficient drug delivery systems widely used to deliver small molecule inhibitors, nucleic acid, and proteins. Using nanoparticles for the targeted delivery of drugs to immune cells provides opportunities to regulate immune cell function. In this review, we summarize the current progress of nanoparticle-based strategies for regulating immune function and discuss the prospects of future nanoparticle design to improve immunotherapy.
{"title":"Progress in nanoparticle-based regulation of immune cells.","authors":"Ya-Nan Fan, Gui Zhao, Yue Zhang, Qian-Ni Ye, Yi-Qun Sun, Song Shen, Yang Liu, Cong-Fei Xu, Jun Wang","doi":"10.1515/mr-2022-0047","DOIUrl":"10.1515/mr-2022-0047","url":null,"abstract":"<p><p>Immune cells are indispensable defenders of the human body, clearing exogenous pathogens and toxicities or endogenous malignant and aging cells. Immune cell dysfunction can cause an inability to recognize, react, and remove these hazards, resulting in cancers, inflammatory diseases, autoimmune diseases, and infections. Immune cells regulation has shown great promise in treating disease, and immune agonists are usually used to treat cancers and infections caused by immune suppression. In contrast, immunosuppressants are used to treat inflammatory and autoimmune diseases. However, the key to maintaining health is to restore balance to the immune system, as excessive activation or inhibition of immune cells is a common complication of immunotherapy. Nanoparticles are efficient drug delivery systems widely used to deliver small molecule inhibitors, nucleic acid, and proteins. Using nanoparticles for the targeted delivery of drugs to immune cells provides opportunities to regulate immune cell function. In this review, we summarize the current progress of nanoparticle-based strategies for regulating immune function and discuss the prospects of future nanoparticle design to improve immunotherapy.</p>","PeriodicalId":74151,"journal":{"name":"Medical review (Berlin, Germany)","volume":"3 2","pages":"152-179"},"PeriodicalIF":0.0,"publicationDate":"2023-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/be/ae/mr-3-2-mr-2022-0047.PMC10471115.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10311383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-04-07eCollection Date: 2023-04-01DOI: 10.1515/mr-2022-0046
Zhiwen Zhao, Dangge Wang, Yaping Li
Nanosized drug delivery systems (NDDSs) have emerged as a powerful tool to optimize drug delivery in complex diseases, including cancer and inflammation. However, the therapeutic effect of NDDSs is still far from satisfactory due to their poor circulation time, low delivery efficiency, and innate toxicity. Fortunately, biomimetic approaches offer new opportunities to develop nanomedicine, which is derived from a variety of native biomolecules including cells, exosomes, bacteria, and so on. Since inheriting the superior biocompatibility and versatile functions of natural materials, biomimetic nanomedicine can mimic biological processes, prolong blood circulation, and lower immunogenicity, serving as a desired platform for precise drug delivery for treating cancer and inflammatory disease. In this review, we outline recent advances in biomimetic NDDSs, which consist of two concepts: biomimetic exterior camouflage and bioidentical molecule construction. We summarize engineering strategies that further functionalized current biomimetic NDDSs. A series of functional biomimetic NDDSs created by our group are introduced. We conclude with an outlook on remaining challenges and possible directions for biomimetic NDDSs. We hope that better technologies can be inspired and invented to advance drug delivery systems for cancer and inflammation therapy.
{"title":"Versatile biomimetic nanomedicine for treating cancer and inflammation disease.","authors":"Zhiwen Zhao, Dangge Wang, Yaping Li","doi":"10.1515/mr-2022-0046","DOIUrl":"10.1515/mr-2022-0046","url":null,"abstract":"<p><p>Nanosized drug delivery systems (NDDSs) have emerged as a powerful tool to optimize drug delivery in complex diseases, including cancer and inflammation. However, the therapeutic effect of NDDSs is still far from satisfactory due to their poor circulation time, low delivery efficiency, and innate toxicity. Fortunately, biomimetic approaches offer new opportunities to develop nanomedicine, which is derived from a variety of native biomolecules including cells, exosomes, bacteria, and so on. Since inheriting the superior biocompatibility and versatile functions of natural materials, biomimetic nanomedicine can mimic biological processes, prolong blood circulation, and lower immunogenicity, serving as a desired platform for precise drug delivery for treating cancer and inflammatory disease. In this review, we outline recent advances in biomimetic NDDSs, which consist of two concepts: biomimetic exterior camouflage and bioidentical molecule construction. We summarize engineering strategies that further functionalized current biomimetic NDDSs. A series of functional biomimetic NDDSs created by our group are introduced. We conclude with an outlook on remaining challenges and possible directions for biomimetic NDDSs. We hope that better technologies can be inspired and invented to advance drug delivery systems for cancer and inflammation therapy.</p>","PeriodicalId":74151,"journal":{"name":"Medical review (Berlin, Germany)","volume":"3 2","pages":"123-151"},"PeriodicalIF":0.0,"publicationDate":"2023-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3f/12/mr-3-2-mr-2022-0046.PMC10471090.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10311381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}